Jean M. Elwing, MD explores the critical role clinical trials play in advancing pulmonary hypertension research. Dr. Elwing examines how patients, clinicians, researchers, and industry partners work together to accelerate the development of new treatments while ensuring safety, scientific rigor, and meaningful outcomes.
Go inside the world's leading PAH Centers of Excellence and discover how they're transforming patient care. Vinicio de Jesus Perez, MD, explores the vital role Centers of Excellence play in advancing the diagnosis, treatment, and future of pulmonary arterial hypertension (PAH).
Stephen Y. Chan, MD, PhD, ATSF examines the next generation of PAH therapies and the scientific breakthroughs redefining what's possible. Learn how basic, translational, and clinical research are converging to identify novel therapeutic targets, accelerate drug development, and shape the future of pulmonary hypertension care.
Sandeep Sahay, MD, MSc, FCCP, ATSF explores the evolution of combination therapy—from the era of single-drug treatment to today's personalized strategies that target multiple disease pathways, including the endothelin, nitric oxide, and prostacyclin pathways.
Sharon I. S. Rounds, MD, ATSF shares a powerful historical perspective on the early days of PH, reflecting on a time when clinicians faced devastating diagnoses with little more than compassion and hope. Discover how those early experiences helped shape decades of innovation, advocacy, and life-changing advances in PAH treatment.
Vallerie V. McLaughlin, MD explores the remarkable story behind prostacyclin, the first successfully targeted pathway for the treatment of pulmonary arterial hypertension (PAH) and its pivotal role in landmark clinical trials, and how the prostacyclin pathway has remained central as treatment algorithms have evolved.
Join Drs. Eric Austin, MD MSCI (Vanderbilt), Rachel K. Hopper, MD (Stanford University), Mary Mullen MD, PhD (Boston Children's Hospital) and Nidhy Varghese, MD (Texas Children’s Hospital) as they take questions and discuss Pulmonary Hypertension Clinical Trials in Young Adults (16-21) and Transitioning from Pediatric to Adult PH Care Teams.